View the latest clinical trials, studies, data, and updates.
To date, the MOVE study has used functional tests as primary outcomes, but recent studies have shown the promise of MRI for FSHD.
The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.
For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.
New clinical research to utilize AI with Fujitsu’s proprietary waveform analysis technology (TDA: topological data analysis), which has been researched and developed jointly with the University of Tokyo Hospital.
“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons. We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.
Diagnostic accuracy of 90% was reported while reducing the average total effective radiation dose per procedure by more than half from 47.5 Gy·cm2 (effective dose: 14.3 mSv) to 25.4 Gy·cm2 (effective dose: 5.8 mSv).